AI Summary

A large population‑based study led by researchers at Karolinska Institutet and published in JAMA Neurology found that people with multiple sclerosis who receive rituximab have a higher risk of developing inflammatory bowel disease, particularly Crohn’s disease, though the absolute risk is low. Rituximab, an anti‑CD20 therapy, is currently the most commonly used disease‑modifying treatment for MS in Sweden. The findings address prior concerns from neurologists about rising inflammatory bowel disease cases among patients on anti‑CD20 therapies, providing the first systematic evidence of this association.

AI summaries can be wrong sometimes—always verify important details using the source article.